UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.

Adams, R; Goey, K; Chibaudel, B; Koopman, M; Punt, C; Arnold, D; Hinke, A; ... Fisher, D; + view all (2021) Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. Cancer Treatment Reviews , 99 , Article 102226. 10.1016/j.ctrv.2021.102226. Green open access

[thumbnail of Brown_Intermitent therapy and plts metaanalysis 11.5.2021 (2).pdf]
Preview
Text
Brown_Intermitent therapy and plts metaanalysis 11.5.2021 (2).pdf - Accepted Version

Download (2MB) | Preview

Abstract

BACKGROUND: Intermittent systemic anti-cancer therapy in patients with advanced colorectal cancer (aCRC) may improve quality of life without compromising overall survival (OS). We aimed to use individual patient data meta-analysis (IPDMA) from multiple randomised controlled trials evaluating intermittent strategies to inform clinical practice. We also aimed to validate whether thrombocytosis as a predictive biomarker identified patients with significantly reduced OS receiving a complete treatment break. PATIENTS AND METHODS: An IPDMA of intermittent strategy impact on survival was undertaken, including all relevant trials in which data were available. Intermittent strategies were classified into two groups: a planned stopping of all therapy ("treatment break strategy"; 6 trials; 2,907 patients) or to the same treatment omitting oxaliplatin ("maintenance strategy"; 3 trials; 1,271 patients). The primary analysis sample was of patients successfully completing induction therapy. Additionally, a pre-planned analysis of the predictive value of thrombocytosis on survival under a continuous versus an intermittent strategy was undertaken. RESULTS: All trials had comparable inclusion criteria. The overall IPDMA of intermittent therapy versus continuous therapy demonstrated no detriment in OS (HR = 1.03 [95% CI 0.93-1.14]), whether from complete break (HR 1.04 [95% CI 0.87-1.26]) or maintenance strategies (HR 0.99 [95% CI 0.87-1.13]). Thrombocytosis was confirmed as a marker of poor prognosis in aCRC, but did not predict for OS detriment from treatment break strategies (interaction HR = 0.97 [95% CI 0.66-1.40] compared to continuous therapy). CONCLUSION: The highest levels of evidence from this IPDMA indicate no detriment in survival for patients receiving an intermittent therapy strategy, either for maintenance or complete break strategies. Although, thrombocytosis is confirmed as a marker of poor prognosis, it is not predictive of poor outcome for patients treated with intermittent therapy. An intermittent chemotherapy strategy can therefore be applied irrespective of baseline platelet count and does not result in inferior OS compared to continuous chemotherapy.

Type: Article
Title: Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ctrv.2021.102226
Publisher version: https://doi.org/10.1016/j.ctrv.2021.102226
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Active monitoring, Chemotherapy, Colorectal cancer, Intermittent therapy, Maintenance therapy, Thrombocytosis, Treatment breaks
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10131576
Downloads since deposit
12Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item